NMS Group is the largest Italian company committed in innovation and research and development in oncology. With 500 total employees, NMS Group employs over 200 qualified researchers involved in research and development, from ‘target validation’ to phase II clinical trials.
The discovery and applied research of Nerviano Medical Sciences – representing the innovative heart of the Group and make it an important and international reference in the field of personalized therapy – integrate with other development activities of a new drug. NMS Group is, in fact, the only reality in Italy able to manage the entire integrated chain of the research and development path: from pre-clinical phase of research, to First-Time-In-Man of clinical phase, up to production and packaging of the finished drug. Nerviano Medical Sciences
Per il farmaco “made in Italy” entrectinib, nuovi incoraggianti risultati con tassi di risposta pari al 79% in fase 1.